Комбинация сертралина с оланзапином в терапии психотической депрессии

At the conclusion of the 12-week trial, investigators found that treatment with olanzapine/sertraline was associated with higher remission rates during the trial than olanzapine/placebo (odds ratio, 1.28; 95% confidence interval, 1.12 – 1.47; P < .001) and that 49% of subjects in the combination therapy group were in remission at their last assessment vs 23.9% of those treated with olanzapine alone.

In addition, the study showed that combination therapy was comparably superior in both younger and older age groups. Although both age groups experienced significant increases in cholesterol and triglyceride concentrations, statistically significant increases in glucose occurred in younger adults.

Further, whereas both age groups experienced weight gain, younger adults gained significantly more weight than their older counterparts — a mean gain of 6.5 vs 3.3 kg.

The study findings suggest that combination therapy is effective and offers physicians and their patients a viable alternative to electroconvulsive therapy, which is generally considered the treatment of choice for this condition but is not without challenges.

The researchers note that although bilateral electroconvulsive therapy has a response rate of 87% when administered in academic centers, the response when delivered in the community setting is much lower, ranging from 30% to 47%. Further, they add, pharmacological treatment may be more practical and less stigmatizing for patients.

STOP-PD: Combination Therapy With Sertraline Plus Olanzapine Effective in the Treatment of Psychotic Depression